Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000442 · ClinicalTrials.gov registry record · Phase 4
Naltrexone for Relapse Prevention
A Phase 4 study of Alcoholism, sponsored by UConn Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT00000442: Completed Phase 4 study of Alcoholism, sponsored by UConn Health.
NCT00000442 is a Phase 4 study of Alcoholism that has completed, run by UConn Health. The registered enrollment target is 57 participants, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000442, a Phase 4 study of Alcoholism, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to evaluate the safety and effectiveness of an injectable slow releasing preparation of naltrexone to reduce alcohol consumption and risk of relapse in alcohol-dependent subjects. Individuals will receive either naltrexone or a placebo injection for a total of three months, with two subsequent followup visits spanning a 6- month period.
Conditions Studied
Interventions
- DRUG naltrexone (Revia)
Study Locations (1)
Pennsylvania
- Department of Psychiatry, University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Est. Completion | 2002-12 |
| Phase | Phase 4 |
What the finished NCT00000442 record still lists
NCT00000442 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 1 intervention - of which naltrexone (Revia) is the first listed.
NCT00000442 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00000442 about?
NCT00000442 is a clinical study titled "Naltrexone for Relapse Prevention". This study is to evaluate the safety and effectiveness of an injectable slow releasing preparation of naltrexone to reduce alcohol consumption and risk of relapse in alcohol-dependent subjects. Individuals will receive either naltrexone or a placebo injection for a total of three months, with two su...
What is the current status of trial NCT00000442?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 57 participants. Estimated completion is 2002-12.
What conditions does trial NCT00000442 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT00000442?
The interventions under investigation include: naltrexone (Revia) (DRUG).
Who is sponsoring clinical trial NCT00000442?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000442 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000442's enrollment target sits among peer trials
57 51st of 65 higher than 15 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naltrexone in AUD Reward Drinkers
RECRUITING · Phase 4
-
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
COMPLETED · Phase 4
-
Naltrexone, Craving, and Drinking
COMPLETED · Phase 4
-
Sertraline Pharmacotherapy for Alcoholism Subtypes
COMPLETED · Phase 4
-
Naltrexone for Heavy Drinking in Young Adults
COMPLETED · Phase 4
-
Managing Alcoholism in People Who Do Not Respond to Naltrexone
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction